Search Results for keywords:"revocation"

The Food and Drug Administration (FDA) has decided to revoke the use of the color additive FD&C Red No. 3 in foods and ingested drugs. This decision was based on evidence showing that FD&C Red No. 3 can cause cancer in male rats, which under the law, makes it unsafe. Although the risk to humans is considered low, the FDA is compelled by law to remove this additive because it has been linked to cancer in animals. The order will take effect on January 15, 2027, but objections can be submitted until February 18, 2025, if anyone is adversely affected by this ruling.

The International Trade Commission announced that it will conduct a full review to decide if removing the antidumping duty order on certain large diameter line pipes from Japan might cause harm to U.S. industries. This review, required by the Tariff Act of 1930, will follow an earlier finding that responses from both domestic and interested parties were adequate. A detailed schedule for the review will be released later, and the Commission will provide access to the proceedings and rules on its official website.

The Drug Enforcement Administration (DEA) decided to revoke the DEA Certificate of Registration for Dr. Willard J. Davis, a doctor in Texas, because he lost his state license to practice medicine, which means he can no longer handle controlled substances legally in Texas. The Texas Medical Board suspended Dr. Davis's medical license on May 16, 2024, and it remained suspended at the time of the decision. Since having a valid state medical license is necessary to maintain DEA registration for dispensing controlled substances, his registration was revoked, and any pending applications related to the registration were denied. This decision will be effective starting April 28, 2025.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Dr. Margaret Sprague, proposing to revoke her Certificate of Registration due to her lack of authority to handle controlled substances in California. This decision followed the revocation of her state medical license by the Medical Board of California. Dr. Sprague did not request a hearing and was deemed in default, admitting the allegations against her. Consequently, the DEA revoked her registration and denied any future applications for registration in California.

The U.S. Department of Commerce has completed an expedited review of the countervailing duty (CVD) order on steel wheels from China, which are 12 to 16.5 inches in diameter. They found that removing this order would likely result in the continuation or recurrence of subsidies that are unfair to U.S. producers. This decision is part of the sunset review process, which revisits such orders to decide if they should be continued. The Commerce Department did not receive any significant responses from Chinese manufacturers, leading to this expedited review and conclusion.

The Food and Drug Administration (FDA) has announced the revocation of the Emergency Use Authorization granted to B. Braun Medical, Inc. This authorization was for the Perfusor Space Syringe Infusion Pump System, Infusomat Space Volumetric Infusion Pump System, and Outlook ES, which were initially approved for emergency use during the COVID-19 pandemic. The revocation, effective October 1, 2024, follows a request from B. Braun Medical, Inc., due to a lack of customer demand and the improved COVID-19 situation. This decision ensures public health and safety is maintained.